Kiniksa Pharmaceuticals International (KNSA) Gains from Investment Securities (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Gains from Investment Securities for 10 years, with the latest figure at $765514.0 in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities rose 1463.23% year-over-year to $765514.0; the trailing twelve-month figure through Mar 2026 stood at $765514.0 (up 1463.23% YoY), and the FY2025 full-year result was $9.4 million, changed N/A from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $765514.0, down from $1.1 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $11.6 million in Q3 2024, with the low at -$11.5 million in Q4 2023.
• Historically, Gains from Investment Securities has averaged $1.5 million across 5 years, with a median of $765514.0 in 2026.
• Annual changes were most pronounced in 2023 — Gains from Investment Securities sank 498.51% — and 2026, when it jumped 1463.23%.
• Kiniksa Pharmaceuticals International's Gains from Investment Securities stood at $2.9 million in 2022, then slumped by 498.51% to -$11.5 million in 2023, then surged by 131.04% to $3.6 million in 2024, then sank by 67.98% to $1.1 million in 2025, then tumbled by 33.03% to $765514.0 in 2026.
• The last three Gains from Investment Securities figures came in at $765514.0 (Q1 2026), $1.1 million (Q4 2025), and $941874.0 (Q3 2025), per Business Quant data.